Skip to main content

Market Overview

Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week

Share:
Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week

Biogen Inc (NASDAQ: BIIB) said its newly approved Spinraza (nusinersen) would be available in just one week time. Spinraza is approved to treat spinal muscular atrophy, a form of muscle weakness.

The company, which got the FDA approval within three months of regulatory filing, said Spinraza will be made available for shipment in the United States to healthcare providers in approximately one week. The drug was approved based on positive results from multiple clinical studies in more than 170 patients.

Biogen licensed the global rights to develop, manufacture and commercialize Spinraza from Ionis Pharmaceuticals Inc (NASDAQ: IONS).

Recent Drug Approvals Through Accelerated Pathway

Following are the recent drugs that have been approved by accelerated pathway:

  • This month, the U.S. Food and Drug Administration granted accelerated approval to Clovis Oncology Inc (NASDAQ: CLVS)'s Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. At that time, Clovis said Rubraca will be available in the United States immediately.
  • In October, Eli Lilly and Co (NYSE: LLY) received accelerated for olaratumab (Lartruvo) to treat adults with advanced soft tissue sarcomas.
  • In September, Sarepta Therapeutics Inc (NASDAQ: SRPT) announced the U.S. Food and Drug Administration has granted accelerated approval for EXONDYS 51 (eteplirsen) for the treatment of Duchenne muscular dystrophy.
 

Related Articles (BIIB + CLVS)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Previews FDA Events Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com